GlobeNewswire by notified

Yara International and Oerth Bio collaborate to tackle crop resilience

Share

Durham, North Carolina, November 15, 2022 — Oerth Bio (pronounced “earth”), an agricultural biotechnology company pioneering targeted protein degraders in plants, and Yara International, a world leading crop nutrition company, today announced a first-of-its-kind collaboration applying Oerth’s novel protein degrader technology to crop efficiency applications.

The collaboration will focus on boosting plant resilience to combat escalating climate stress impacting crop production and farm economics. The companies will co-develop novel products to improve nutrient use efficiency and strengthen plant resilience to climate change. By linking Yara’s agronomic expertise in crop physiology and crop nutrition to Oerth’s specialization in rational design of plant protein degraders, the collaboration will develop unique products to activate precision plant stress tolerance.

“This collaboration will be a game-changing win for farmers — a completely new product range to safeguard crop quality and yield, even as climate challenges increase and become more unpredictable.”

Lars Roesag, EVP Corporate Development & Deputy CEO, Yara International

Yara sees tremendous promise in the new technology, as indicated by Yara Senior Vice President of Agronomy and R&D, Markus Himken, “This collaboration will catapult Yara’s competitive footprint, offering farmers plant nutrition solutions specifically targeting plant resilience and improved crop quality — setting a new sustainable agriculture paradigm.”

The collaboration merges Yara’s mission for a nature-positive food future, and Oerth’s vision that protein degrader technology will transform agriculture. Oerth’s Attune™ platform harnesses a naturally occurring protein recycling system that precisely tunes climate-adaptable crops.

The companies are devoted to the idea that human health begins with plant health. They share a foundational commitment to sustainable and nutritious food system solutions, as Apostolos Klontzaris, Senior Vice President of Corporate and Business Development at Oerth Bio remarked, “This will be the first in a series of solutions that will enable crops to withstand climate change, enhance input efficiency, and improve food nutrient profiles. We are inspiring and motivating the necessary transition to high-quality food. Such mission-critical collaborations symbolize our longstanding commitment to humanity.

“We believe PROTAC® degrader technology is the sustainable answer to a safe, productive, resilient, and more nutritious food system. By partnering with agricultural leaders like Yara, we are poised to deliver tangible benefit to farmers, as they face fast emerging operational complexity and climate challenges."

John Dombrosky, CEO, Oerth Bio

About Yara

Yara grows knowledge to responsibly feed the world and protect the planet. Supporting our vision of a world without hunger and a planet respected, we pursue a strategy of sustainable value growth, promoting climate-friendly crop nutrition and zero-emission energy solutions. Yara’s ambition is focused on growing a nature positive food future that creates value for our customers, shareholders and society at large and delivers a more sustainable food value chain.

To achieve our ambition, we have taken the lead in developing digital farming tools for precision farming and work closely with partners throughout the food value chain to improve the efficiency and sustainability of food production. Through our focus on clean ammonia production, we aim to enable the hydrogen economy, driving a green transition of shipping, fertilizer production and other energy intensive industries.

Founded in 1905 to solve the emerging famine in Europe, Yara has established a unique position as the industry’s only global crop nutrition company. We operate an integrated business model with around 17,000 employees and operations in over 60 countries, with a proven track record of strong returns. In 2021, Yara reported revenues of USD 16.6 billion.

For more information about the company, please visit www.yara.com

About Oerth Bio

Oerth Bio’s protein degrader technology for agriculture, aims to combine powerful farm efficacy with next-generation environmental sustainability. The technology is designed to deliver unparalleled safety of food and farm, while achieving superior field performance for farmers.

The core technological innovations driving Oerth Bio’s progress are:

• PROTAC® Molecules

PROteolysis TArgeting Chimeras (PROTAC) compounds are biologically enabled molecules designed to induce the modulation of specific proteins via the ubiquitin proteasome system. Each region of the PROTAC molecule plays a role in its specificity and potency.

• Attune™ Platform 

Attune™ is Oerth Bio’s proprietary R&D platform for developing PROTAC molecules for agriculture. Through a rational target-based design process, the platform creates and optimizes molecules for specific crop applications and outcomes.

PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.

www.oerthbio.com

Media contact

Sr. Director, Communications
Oerth Bio
E-mail: laura.schuchart@oerthbio.com


Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Monthly information regarding the total number of voting rights and total number of shares of the Company as of November 30, 20228.12.2022 22:30:00 CET | Press release

Monthly information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2022 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of sharesTotal number of voting rights11/30/2022 94,137,145 Total gross of voting rights: 94,137,145 Total net* of voting rights: 93,966,891 * Total net = total number of voting rights attached to shares – shares without voting rights Attachment PDF Version

Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants8.12.2022 22:00:00 CET | Press release

Company announcement – No. 57 / 2022 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark and Boston, MA, U.S. December 8, 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 64,919 divided into 64,919 new shares with a nominal value of DKK 1 each. The increase is a consequence of the exercise of warrants granted under several of Zealand Pharma's employee warrant programs. Employee warrant programs are part of Zealand Pharma’s incentive scheme, and each warrant gives the owner the right to subscribe for one new Zealand Pharma share at a prespecified price, the exercise price, in specific predefined time periods before expiration. For a more detailed description of Zealand Pharma’s warrant programs, see the company’s Articles o

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such8.12.2022 21:40:00 CET | Press release

COPENHAGEN, Denmark, December 8, 2022 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such. 1.Details of the person discharging managerial responsibilities/person closely associateda)NamePaul Chaplin2.Reason for the notificationa)Position/status President and Chief Executive Officer of Bavarian Nordic A/S b)Initial notification/AmendmentInitial notification3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitora)NameBavarian Nordic A/Sb)LEI2138006JCDVYIN6INP514.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducteda)Description of the financial instrument, type of instrument Identification codeWarrants DK0015

Indberetning af ledende medarbejdere og disses nærtståendes transaktioner med Bavarian Nordic aktier og tilknyttede værdipapirer8.12.2022 21:40:00 CET | pressemeddelelse

KØBENHAVN, Danmark, 8. december 2022 – Bavarian Nordic A/S (OMX: BAVA) har dags dato modtaget oplysninger om følgende transaktioner med selskabets aktie/tilknyttede værdipapirer, foretaget af ledende medarbejdere og/eller personer/firmaer der er nærtstående til disse. 1.Nærmere oplysninger om personen med ledelsesansvar/personen med nær tilknytning til dennea)NavnPaul Chaplin2.Årsag til indberetningena)Stilling/titelAdministrerende direktør i Bavarian Nordic A/Sb)Første indberetning/ændringFørste indberetning3.Nærmere oplysninger om udstederen, deltageren på markedet for emissionskvoter, auktionsplatformen, auktionsholderen eller den auktionstilsynsførendea)NavnBavarian Nordic A/Sb)LEI-kode2138006JCDVYIN6INP514.Nærmere oplysninger om transaktionen/transaktionerne: gentages for i) hver type instrument, ii) hver type transaktion, iii) hver dato og iv) hvert sted, hvor der er udført transaktionera)Beskrivelse af det finansielle instrument, instrumenttypen IdentifikationskodeTegningsoption

Bavarian Nordic iværksætter nyt incitamentsprogram for koncernledelsen og udvalgte medarbejdere8.12.2022 21:35:00 CET | pressemeddelelse

KØBENHAVN, Danmark, 8. december 2022 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at bestyrelsen har besluttet at udstede tegningsoptioner til koncernledelsen og udvalgte medarbejdere i Bavarian Nordic koncernen. Som et nyt initiativ vil erhvervelsen (vesting) af tegningsoptioner for medlemmer af koncernledelsen være baseret på succesfuld opnåelse af relevante Key Performance Indicators (KPI’er). Beslutningen er truffet i henhold til generalforsamlingens bemyndigelser til bestyrelsen, jf. vedtægternes § 5b og 5c, og i overensstemmelse med selskabets vederlagspolitik. Der tildeles i alt 248.787 tegningsoptioner til medlemmer af koncernledelsen til en udnyttelseskurs på DKK 224,70 pr. aktie, svarende til markedskursen for Bavarian Nordics aktie på tildelingstidspunktet. Erhvervelse af tegningsoptionerne er betinget af forudgående opfyldelse af KPI’er, som fastsættes af bestyrelsen. Der tildeles i alt 683.264 tegningsoptioner til udvalgte medarbejdere i Bavarian Nordic koncernen til